aspirin has been researched along with Dyspnea in 54 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Dyspnea: Difficult or labored breathing.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Nearly 20% of patients on ticagrelor experience dyspnea, which may lead to treatment discontinuation in up to one-third of cases." | 9.69 | Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Ielasi, A; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Stefanini, GG; Steg, PG; Vogel, B; Weisz, G; Witzenbichler, B; Zhang, Z, 2023) |
| "Dyspnea is commonly associated with ticagrelor therapy, but was not associated in this study with any adverse change in cardiac or pulmonary function." | 9.14 | Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. ( Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Patil, SB; Storey, RF; Tantry, US; Teng, R; Wei, C, 2010) |
| "To study the safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, and to determine whether it cross-reacts with asthma in patients with aspirin-exacerbated respiratory disease (AERD)." | 9.12 | Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. ( Ahmed, I; El Gaafary, M; El Miedany, Y; Youssef, S, 2006) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 7.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient." | 7.74 | Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion. ( Escarment, J; Lions, C; Ould-Ahmed, M; Petitjeans, F; Wey, PF, 2008) |
| "Guacetisal was administered to a group of patients suffering from chronic asthmatic bronchitis." | 7.66 | [Clinico-functional data concerning chronic asthmatic bronchitis patients treated wih guacetisal]. ( Bande, G; Coghe, M; Meloni, M; Nonne, G, 1981) |
| "Nearly 20% of patients on ticagrelor experience dyspnea, which may lead to treatment discontinuation in up to one-third of cases." | 5.69 | Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention. ( Angiolillo, DJ; Baber, U; Briguori, C; Cao, D; Cohen, DJ; Collier, T; Dangas, G; Dudek, D; Escaned, J; Gibson, M; Gil, R; Huber, K; Ielasi, A; Kaul, U; Kornowski, R; Krucoff, MW; Kunadian, V; Mehran, R; Mehta, S; Moliterno, DJ; Ohman, EM; Pivato, CA; Pocock, S; Sardella, G; Sartori, S; Sharma, SK; Shlofmitz, R; Stefanini, GG; Steg, PG; Vogel, B; Weisz, G; Witzenbichler, B; Zhang, Z, 2023) |
| "Dyspnea was diagnosed in 157 (4." | 5.35 | Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. ( Atar, D; Kuliczkowski, W; Pokov, I; Serebruany, V; Vahabi, J, 2008) |
| "Dyspnea is commonly associated with ticagrelor therapy, but was not associated in this study with any adverse change in cardiac or pulmonary function." | 5.14 | Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. ( Bliden, KP; Butler, K; Ecob, R; Gurbel, PA; Karunakaran, A; Patil, SB; Storey, RF; Tantry, US; Teng, R; Wei, C, 2010) |
| "To study the safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, and to determine whether it cross-reacts with asthma in patients with aspirin-exacerbated respiratory disease (AERD)." | 5.12 | Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease. ( Ahmed, I; El Gaafary, M; El Miedany, Y; Youssef, S, 2006) |
| "Viral pericarditis is the most common cause of acute pericarditis and it is typically responsive to aspirin or nonsteroidal anti-inflammatory drugs." | 4.95 | Tuberculous and Infectious Pericarditis. ( Chang, SA, 2017) |
| "Current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome (ACS), primarily based on a single large randomized clinical trial." | 3.96 | Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. ( Bikdeli, B; Cho, J; Gupta, A; Hripcsak, G; Kim, J; Krumholz, HM; Londhe, A; Madigan, D; Park, J; Park, RW; Reich, CG; Rho, Y; Ryan, PB; Schuemie, M; Siapos, A; Suchard, MA; Weaver, J; You, SC, 2020) |
| "Current clinical practice guidelines recommend dual antiplatelet therapy with aspirin and clopidogrel or prasugrel for patients with acute coronary syndrome (ACS)." | 3.77 | Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome. ( Bonafede, M; Deitelzweig, SB; Gdovin Bergeson, J; Graham, J; Jing, Y; Liffmann, D; Makenbaeva, D, 2011) |
| "This report describes a case of a probable interaction between topical econazole lotion 1% and acenocoumarol that resulted in overanticoagulation and a life-threatening laryngeal hematoma in this elderly patient." | 3.74 | Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion. ( Escarment, J; Lions, C; Ould-Ahmed, M; Petitjeans, F; Wey, PF, 2008) |
| " Anticoagulants are effective in stroke prevention in atrial fibrillation with aspirin being a less effective alternative." | 3.72 | Left ventricular systolic dysfunction and atrial fibrillation in older people in the community--a need for screening? ( Buchalter, M; Burr, ML; Ho, SF; O'Mahony, MS; Steward, JA, 2004) |
| "Between 8-20 percent of adult asthmatics experience bronchospasm following ingestion of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs)." | 3.70 | NSAID-induced bronchospasm--a common and serious problem. A report from MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority. ( Sturtevant, J, 1999) |
| "Guacetisal was administered to a group of patients suffering from chronic asthmatic bronchitis." | 3.66 | [Clinico-functional data concerning chronic asthmatic bronchitis patients treated wih guacetisal]. ( Bande, G; Coghe, M; Meloni, M; Nonne, G, 1981) |
| "Myocardial infarction is common among the elderly." | 2.39 | Myocardial infarction. Considerations for geriatric patients. ( Sinclair, D, 1994) |
| "Acute pericarditis has a wide spectrum of clinical presentations largely depending on underlying aetiologies." | 1.62 | Age- and sex-based differences in patients with acute pericarditis. ( Antonopoulos, AS; Lazaros, G; Lazarou, E; Tousoulis, D; Vassilopoulos, D; Vlachopoulos, C; Vogiatzi, G, 2021) |
| "Shrinking lung syndrome is characterized by pulmonary compromise secondary to unilateral or bilateral paralysis of the diaphragm." | 1.37 | Shrinking lung syndrome in pregnancy complicated by antiphospholipid antibody syndrome. ( Brost, BC; DeStephano, CC; Meena, M; Watson, WJ, 2011) |
| "Dyspnea was diagnosed in 157 (4." | 1.35 | Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. ( Atar, D; Kuliczkowski, W; Pokov, I; Serebruany, V; Vahabi, J, 2008) |
| "A nonanemic chronic lymphocytic leukemia patient with nearly 500,000 lymphocytes/microL underwent leukapheresis when she presented with CNS symptoms and retinal vascular engorgement." | 1.27 | Lymphocyte aggregation in response to adrenergic stimulation. ( Hammerschmidt, DE; Husak, M; Jacob, HS; Jeanneret, C; Lobell, M, 1988) |
| "A patient with systemic lupus erythematosus presented with moderately severe restrictive and obstructive ventilatory defects." | 1.26 | Pulmonary function abnormalities in systemic lupus erythematosus responsive to glucocorticoid therapy. ( Al-Bazzaz, F; Venizelos, PC, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (22.22) | 18.7374 |
| 1990's | 3 (5.56) | 18.2507 |
| 2000's | 8 (14.81) | 29.6817 |
| 2010's | 22 (40.74) | 24.3611 |
| 2020's | 9 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Sheng, XY | 1 |
| An, HJ | 1 |
| He, YY | 1 |
| Ye, YF | 1 |
| Zhao, JL | 1 |
| Li, S | 1 |
| Angiolillo, DJ | 1 |
| Cao, D | 1 |
| Sartori, S | 1 |
| Baber, U | 1 |
| Dangas, G | 1 |
| Zhang, Z | 1 |
| Vogel, B | 1 |
| Kunadian, V | 1 |
| Briguori, C | 1 |
| Cohen, DJ | 1 |
| Collier, T | 1 |
| Dudek, D | 1 |
| Gibson, M | 1 |
| Gil, R | 1 |
| Huber, K | 1 |
| Kaul, U | 1 |
| Kornowski, R | 1 |
| Krucoff, MW | 1 |
| Ielasi, A | 1 |
| Stefanini, GG | 1 |
| Pivato, CA | 1 |
| Mehta, S | 1 |
| Moliterno, DJ | 1 |
| Ohman, EM | 1 |
| Escaned, J | 1 |
| Sardella, G | 1 |
| Sharma, SK | 1 |
| Shlofmitz, R | 1 |
| Weisz, G | 1 |
| Witzenbichler, B | 1 |
| Steg, PG | 2 |
| Pocock, S | 1 |
| Mehran, R | 1 |
| Khanra, D | 2 |
| Soni, S | 1 |
| Ola, R | 1 |
| Duggal, B | 2 |
| Gimbel, ME | 1 |
| Vos, GJA | 1 |
| Nguyen, TA | 1 |
| Kelder, JC | 1 |
| Ten Berg, JM | 1 |
| Furtado, RHM | 1 |
| Venkateswaran, RV | 1 |
| Nicolau, JC | 1 |
| Gurmu, Y | 1 |
| Bhatt, DL | 1 |
| Storey, RF | 2 |
| Magnani, G | 1 |
| Goto, S | 1 |
| Dellborg, M | 1 |
| Kamensky, G | 1 |
| Isaza, D | 1 |
| Aylward, P | 1 |
| Johanson, P | 1 |
| Bonaca, MP | 1 |
| Hertz, JT | 1 |
| Sakita, FM | 1 |
| Kweka, GL | 1 |
| Bloomfield, GS | 1 |
| Bartlett, JA | 1 |
| Tarimo, TG | 1 |
| Temu, G | 1 |
| Bettger, JP | 1 |
| Thielman, NM | 1 |
| Lazaros, G | 1 |
| Antonopoulos, AS | 1 |
| Lazarou, E | 1 |
| Vlachopoulos, C | 1 |
| Vogiatzi, G | 1 |
| Vassilopoulos, D | 1 |
| Tousoulis, D | 1 |
| Kofman, AD | 1 |
| Sizemore, EK | 1 |
| Detelich, JF | 1 |
| Albrecht, B | 1 |
| Piantadosi, AL | 1 |
| You, SC | 1 |
| Rho, Y | 1 |
| Bikdeli, B | 1 |
| Kim, J | 1 |
| Siapos, A | 1 |
| Weaver, J | 1 |
| Londhe, A | 1 |
| Cho, J | 1 |
| Park, J | 1 |
| Schuemie, M | 1 |
| Suchard, MA | 1 |
| Madigan, D | 1 |
| Hripcsak, G | 1 |
| Gupta, A | 1 |
| Reich, CG | 1 |
| Ryan, PB | 1 |
| Park, RW | 1 |
| Krumholz, HM | 1 |
| Cattalini, M | 1 |
| Della Paolera, S | 1 |
| Zunica, F | 1 |
| Bracaglia, C | 1 |
| Giangreco, M | 1 |
| Verdoni, L | 1 |
| Meini, A | 1 |
| Sottile, R | 1 |
| Caorsi, R | 1 |
| Zuccotti, G | 1 |
| Fabi, M | 1 |
| Montin, D | 1 |
| Meneghel, A | 1 |
| Consolaro, A | 1 |
| Dellepiane, RM | 1 |
| Maggio, MC | 1 |
| La Torre, F | 1 |
| Marchesi, A | 1 |
| Simonini, G | 1 |
| Villani, A | 1 |
| Cimaz, R | 1 |
| Ravelli, A | 1 |
| Taddio, A | 1 |
| Chang, SA | 1 |
| Cohen, P | 1 |
| Musisca, N | 1 |
| Binder, W | 1 |
| DeFilippis, EM | 1 |
| Tsao, AL | 1 |
| Loscalzo, J | 1 |
| Taylor, M | 1 |
| Boudoulas, KD | 1 |
| Jüni, P | 1 |
| Vranckx, P | 1 |
| Valgimgli, M | 1 |
| Serruys, P | 1 |
| Windecker, S | 1 |
| Martí, D | 1 |
| Sanmartín, M | 1 |
| Tiwari, P | 1 |
| Shrivastava, Y | 1 |
| Brucculeri, F | 1 |
| Oppezzo, E | 1 |
| Taverna, GG | 1 |
| Dell'era, G | 1 |
| Demarchi, PG | 1 |
| Taverna, G | 1 |
| Mercogliano, D | 1 |
| Barbero, S | 1 |
| Lee, M | 1 |
| Green, SA | 1 |
| Cherian, T | 1 |
| Devlin, G | 1 |
| Lip, GY | 1 |
| Fauchier, L | 1 |
| Freedman, SB | 1 |
| Van Gelder, I | 1 |
| Natale, A | 1 |
| Gianni, C | 1 |
| Nattel, S | 1 |
| Potpara, T | 1 |
| Rienstra, M | 1 |
| Tse, HF | 1 |
| Lane, DA | 1 |
| Zhao, YT | 1 |
| Tu, I | 1 |
| Godfrey, A | 1 |
| Cajigas, HR | 1 |
| Ozdemir, K | 1 |
| Aygül, N | 1 |
| Can, I | 1 |
| Aribaş, A | 1 |
| Serebruany, V | 1 |
| Pokov, I | 1 |
| Kuliczkowski, W | 1 |
| Vahabi, J | 1 |
| Atar, D | 1 |
| Wey, PF | 1 |
| Petitjeans, F | 1 |
| Lions, C | 1 |
| Ould-Ahmed, M | 1 |
| Escarment, J | 1 |
| Cohen, M | 1 |
| Rocher, F | 1 |
| Brunschwig, C | 1 |
| Lebrun, C | 1 |
| Sato, S | 1 |
| Nagao, R | 1 |
| Hujioka, T | 1 |
| Suzuki, K | 1 |
| Tsuyuki, K | 1 |
| Hoshika, A | 1 |
| Bliden, KP | 1 |
| Patil, SB | 1 |
| Karunakaran, A | 1 |
| Ecob, R | 1 |
| Butler, K | 1 |
| Teng, R | 1 |
| Wei, C | 1 |
| Tantry, US | 1 |
| Gurbel, PA | 1 |
| Doğan, M | 1 |
| Akdemir, R | 1 |
| Biçer Yeşilay, A | 1 |
| Kılıç, H | 1 |
| Karakurt, O | 1 |
| Balcı, MM | 1 |
| Orçan, S | 1 |
| Abergel, E | 1 |
| Nikolsky, E | 1 |
| Maron, BA | 1 |
| Shekar, PS | 1 |
| Goldhaber, SZ | 1 |
| Meena, M | 1 |
| DeStephano, CC | 1 |
| Watson, WJ | 1 |
| Brost, BC | 1 |
| Bonafede, M | 1 |
| Jing, Y | 1 |
| Gdovin Bergeson, J | 1 |
| Liffmann, D | 1 |
| Makenbaeva, D | 1 |
| Graham, J | 1 |
| Deitelzweig, SB | 1 |
| Al-Rashid, F | 1 |
| Konorza, TF | 1 |
| Plicht, B | 1 |
| Wendt, D | 1 |
| Thielmann, M | 1 |
| Jakob, H | 1 |
| Erbel, R | 1 |
| Kahlert, P | 1 |
| Yi, HJ | 1 |
| Cheong, MA | 1 |
| Kim, DW | 1 |
| Macchia, L | 1 |
| Caiaffa, MF | 1 |
| Vacca, A | 1 |
| Tursi, A | 1 |
| ATTAL, C | 1 |
| Ho, SF | 1 |
| O'Mahony, MS | 1 |
| Steward, JA | 1 |
| Burr, ML | 1 |
| Buchalter, M | 1 |
| El Miedany, Y | 1 |
| Youssef, S | 1 |
| Ahmed, I | 1 |
| El Gaafary, M | 1 |
| Bartolucci, L | 1 |
| Canini, F | 1 |
| Fioroni, E | 1 |
| Pinchi, G | 1 |
| Carosi, M | 1 |
| Marvulli, G | 1 |
| Partipilo, N | 1 |
| Mora, P | 1 |
| Levi, P | 1 |
| Marostica, G | 1 |
| Pelucco, D | 1 |
| Bernabò Di Negro, G | 1 |
| Ravazzoni, C | 1 |
| Venizelos, PC | 1 |
| Al-Bazzaz, F | 1 |
| Bande, G | 1 |
| Coghe, M | 1 |
| Meloni, M | 1 |
| Nonne, G | 1 |
| Sinclair, D | 1 |
| Herlitz, J | 1 |
| Haglid, M | 1 |
| Hartford, M | 1 |
| Karlson, BW | 1 |
| Karlsson, T | 1 |
| Lindelöw, B | 1 |
| Caidahl, K | 1 |
| Sturtevant, J | 1 |
| Frith, P | 1 |
| Dolovich, J | 1 |
| Hargreave, FE | 1 |
| Hammerschmidt, DE | 1 |
| Jeanneret, C | 1 |
| Husak, M | 1 |
| Lobell, M | 1 |
| Jacob, HS | 1 |
| Marquardt, H | 1 |
| Muranaka, M | 1 |
| Okumura, H | 1 |
| Takeda, K | 1 |
| Koizumi, K | 1 |
| Igarashi, H | 1 |
| Coldwell, BB | 1 |
| Boyd, EM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Multi-centre Randomised, Double-blind, Double-dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of Ticagrelor Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disea[NCT00528411] | Phase 2 | 123 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 96.59 |
| Clopidogrel | 96.78 |
| Placebo | 97.58 |
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 57.96 |
| Clopidogrel | 61.91 |
| Placebo | 59.92 |
FEV1 is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.79 |
| Clopidogrel | 2.71 |
| Placebo | 2.94 |
FVC is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 3.72 |
| Clopidogrel | 3.73 |
| Placebo | 4.03 |
FRC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.79 |
| Clopidogrel | 2.89 |
| Placebo | 2.91 |
FEF25-75 is measured by Spirometry, the unit is Liter/Second. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter/second (Mean) |
|---|---|
| Ticagrelor | 2.88 |
| Clopidogrel | 2.70 |
| Placebo | 2.50 |
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute (NCT00528411)
Timeframe: Baseline
| Intervention | Liter/minute (Mean) |
|---|---|
| Ticagrelor | 12.92 |
| Clopidogrel | 12.17 |
| Placebo | 12.06 |
NT-proBNP is measured by clinical lab, the unit is pg/mL. (NCT00528411)
Timeframe: Baseline
| Intervention | pg/ml (Mean) |
|---|---|
| Ticagrelor | 163.34 |
| Clopidogrel | 185.98 |
| Placebo | 145.41 |
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio. (NCT00528411)
Timeframe: Baseline
| Intervention | Ratio (Mean) |
|---|---|
| Ticagrelor | 75.01 |
| Clopidogrel | 73.04 |
| Placebo | 73.13 |
RV is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 1.94 |
| Clopidogrel | 2.01 |
| Placebo | 1.91 |
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute. (NCT00528411)
Timeframe: Baseline
| Intervention | Breaths/minute (Mean) |
|---|---|
| Ticagrelor | 14.79 |
| Clopidogrel | 14.15 |
| Placebo | 15.5 |
DLCOSB is measured by Body Box Plethysmography, the unit is Percent. (NCT00528411)
Timeframe: Baseline
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 17.00 |
| Clopidogrel | 17.29 |
| Placebo | 15.83 |
VT is measured by Body Box Plethysmography, the unit is Liter/Minute. (NCT00528411)
Timeframe: Baseline
| Intervention | Liters/minute (Mean) |
|---|---|
| Ticagrelor | 0.96 |
| Clopidogrel | 0.89 |
| Placebo | 0.89 |
TLC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: Baseline
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 5.78 |
| Clopidogrel | 5.83 |
| Placebo | 6.10 |
FEV1 is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.77 |
| Clopidogrel | 2.74 |
| Placebo | 2.95 |
FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Ratio (Mean) |
|---|---|
| Ticagrelor | 74.71 |
| Clopidogrel | 72.84 |
| Placebo | 74.27 |
FVC is measured by Spirometry, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 3.70 |
| Clopidogrel | 3.78 |
| Placebo | 3.98 |
DLCOSB is measured by Body Box Plethysmography, the unit is Percent. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 16.38 |
| Clopidogrel | 16.53 |
| Placebo | 16.09 |
EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percent (Mean) |
|---|---|
| Ticagrelor | 60.70 |
| Clopidogrel | 62.38 |
| Placebo | 60.73 |
FEF25-75 is measured by Spirometry, the unit is Liter/Second. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter/second (Mean) |
|---|---|
| Ticagrelor | 2.77 |
| Clopidogrel | 2.67 |
| Placebo | 2.91 |
FRC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 2.73 |
| Clopidogrel | 2.79 |
| Placebo | 2.75 |
NT-proBNP is measured by clinical lab, the unit is pg/mL. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | pg/ml (Mean) |
|---|---|
| Ticagrelor | 139.88 |
| Clopidogrel | 214.43 |
| Placebo | 140.68 |
RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Breaths/minute (Mean) |
|---|---|
| Ticagrelor | 15.21 |
| Clopidogrel | 15.10 |
| Placebo | 14.91 |
RV is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 1.88 |
| Clopidogrel | 1.97 |
| Placebo | 1.90 |
SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Percentage (Mean) |
|---|---|
| Ticagrelor | 97.73 |
| Clopidogrel | 97.35 |
| Placebo | 98.56 |
TLC is measured by Body Box Plethysmography, the unit is Liter. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter (Mean) |
|---|---|
| Ticagrelor | 5.70 |
| Clopidogrel | 5.85 |
| Placebo | 5.96 |
VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liter/minute (Mean) |
|---|---|
| Ticagrelor | 13.69 |
| Clopidogrel | 13.14 |
| Placebo | 11.45 |
VT is measured by Body Box Plethysmography, the unit is Liter/Minute. (NCT00528411)
Timeframe: 6-week post treatment
| Intervention | Liters/minute (Mean) |
|---|---|
| Ticagrelor | 0.92 |
| Clopidogrel | 0.93 |
| Placebo | 0.83 |
IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: At 2 hours after first dose of study drug
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 93.15 |
| Clopidogrel | 31.05 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 0 hour before last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 74.53 |
| Clopidogrel | 51.75 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 0.5 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 45.39 |
| Clopidogrel | 4.71 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 1 hour after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 86.71 |
| Clopidogrel | 15.83 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 120 hours - Day 5 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 0.0 |
| Clopidogrel | 21.15 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 168 hours - Day 7 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 0.0 |
| Clopidogrel | 6.32 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 2 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 91.49 |
| Clopidogrel | 62.96 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 24 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 87.29 |
| Clopidogrel | 49.64 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 24 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 55.18 |
| Clopidogrel | 53.91 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 240 hours - Day 10 after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 1.64 |
| Clopidogrel | 0.98 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 4 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 98.39 |
| Clopidogrel | 40.87 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 4 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 96.10 |
| Clopidogrel | 61.80 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 48 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 30.94 |
| Clopidogrel | 45.79 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 72 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 11.76 |
| Clopidogrel | 21.09 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 8 hours after first dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 96.99 |
| Clopidogrel | 46.90 |
IPA(%)=(PAb-PAt)/PAb*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. (NCT00528411)
Timeframe: 8 hours after last dose
| Intervention | Percentage (Median) |
|---|---|
| Ticagrelor | 88.31 |
| Clopidogrel | 61.31 |
IPA(%)=(PAb-PAt)/PAb*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour. (NCT00528411)
Timeframe: 4 to 72 Hours after last dose of study drug
| Intervention | Percentage/Hour (Least Squares Mean) |
|---|---|
| Ticagrelor | -1.037 |
| Clopidogrel | -0.482 |
5 reviews available for aspirin and Dyspnea
| Article | Year |
|---|---|
High-Dose Clopidogrel versus Ticagrelor in CYP2C19 intermediate or poor metabolizers after percutaneous coronary intervention: A Meta-Analysis of Randomized Trials.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Dyspnea; Hemorrhage; Humans | 2022 |
Tuberculous and Infectious Pericarditis.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal | 2017 |
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
Ticagrelor: an investigational oral antiplatelet treatment for reduction of major adverse cardiac events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine; Aspirin; Blood Platelets; Clopidogrel; Dyspnea; Humans; Platelet | 2010 |
Myocardial infarction. Considerations for geriatric patients.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; A | 1994 |
8 trials available for aspirin and Dyspnea
| Article | Year |
|---|---|
Dyspnea-Related Ticagrelor Discontinuation After Percutaneous Coronary Intervention.
Topics: Aspirin; Drug Therapy, Combination; Dyspnea; Hemorrhage; Humans; Percutaneous Coronary Intervention; | 2023 |
Caffeinated Beverage Intake, Dyspnea With Ticagrelor, and Cardiovascular Outcomes: Insights From the PEGASUS-TIMI 54 Trial.
Topics: Aged; Aspirin; Beverages; Caffeine; Double-Blind Method; Dual Anti-Platelet Therapy; Dyspnea; Female | 2020 |
Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study.
Topics: Adenosine; Aged; Aspirin; Clopidogrel; Coronary Disease; Double-Blind Method; Dyspnea; Female; Heart | 2010 |
Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Provoca | 2006 |
[Clinical evaluation of the therapeutic effectiveness of a new drug with anti-inflammatory-balsamic action, guacetisal, in respiratory tract diseases].
Topics: Adolescent; Adult; Aged; Aspirin; Bronchitis; Bronchopneumonia; Chronic Disease; Clinical Trials as | 1981 |
[Preliminary study of guacetisal in chronic bronchitis].
Topics: Aged; Aspirin; Bronchitis; Chronic Disease; Clinical Trials as Topic; Cough; Dyspnea; Humans; Male; | 1981 |
[Broncaspin in respiratory diseases in pediatrics. Clinical contribution].
Topics: Aspirin; Bronchitis; Bronchopneumonia; Child; Child, Preschool; Clinical Trials as Topic; Cough; Dys | 1981 |
[The use of B.I. 1070/P (guacetisal) in inflammatory bronchopneumopathies in the acute phase].
Topics: Acute Disease; Adolescent; Adult; Aged; Aspirin; Blood; Bronchitis; Bronchopneumonia; Clinical Trial | 1981 |
41 other studies available for aspirin and Dyspnea
| Article | Year |
|---|---|
Acute attack of gout precipitated by concomitant use of aspirin and diuretic in a rheumatic mitral stenosis patient.
Topics: Adult; Aspirin; Colchicine; Diagnosis, Differential; Diuretics; Dyspnea; Gout; Gout Suppressants; Hu | 2019 |
Reasons for early discontinuing or switching of antiplatelet therapy in elderly patients after acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Artery Bypass; Depr | 2020 |
Effect of a Triage-Based Screening Protocol on Diagnosis and Treatment of Acute Coronary Syndrome in a Tanzanian Emergency Department: A Prospective Pre-Post Study.
Topics: Acute Coronary Syndrome; Aspirin; Body Mass Index; Chest Pain; Dyspnea; Electrocardiography; Emergen | 2020 |
Age- and sex-based differences in patients with acute pericarditis.
Topics: Acute Disease; Adult; Age Distribution; Age Factors; Aged; Anti-Inflammatory Agents; Anti-Inflammato | 2021 |
A young adult with COVID-19 and multisystem inflammatory syndrome in children (MIS-C)-like illness: a case report.
Topics: Adult; Aspirin; Betacoronavirus; Coronavirus Infections; Cough; COVID-19; COVID-19 Drug Treatment; D | 2020 |
Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Algorithms; Aspirin; Case-Control Studies; | 2020 |
Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey.
Topics: Age Distribution; Antirheumatic Agents; Aspirin; C-Reactive Protein; Child; Child, Preschool; Corona | 2021 |
A 57-year-old man with a spontaneous carotid artery dissection.
Topics: Aspirin; Carotid Artery, Internal, Dissection; Dyspnea; Fibrinolytic Agents; Humans; Male; Medical H | 2018 |
Dyspnea and Edema in a Woman With Antiphospholipid Syndrome.
Topics: Antiphospholipid Syndrome; Aspirin; Dyspnea; Echocardiography; Edema; Female; Fluoroscopy; Heart Fai | 2018 |
24-year-old with history of smoking tobacco and cannabis · dyspnea · chest tightness.
Topics: Adult; Antihypertensive Agents; Aspirin; Chest Pain; Coronary Vasospasm; Dyspnea; Humans; Lisinopril | 2018 |
Dyspnoea in the GLOBAL LEADERS trial - Authors' reply.
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Dyspnea; Humans; Ticagrelor | 2019 |
Dyspnoea in the GLOBAL LEADERS trial.
Topics: Aspirin; Clopidogrel; Drug-Eluting Stents; Dyspnea; Humans; Ticagrelor | 2019 |
Systolic anterior motion: an unusual cause of late mitral valve repair failure.
Topics: Adrenergic beta-Antagonists; Anticoagulants; Aspirin; Cardiomyopathy, Hypertrophic; Dyspnea; Echocar | 2019 |
[A rare case of giant coronary aneurysms involving both coronary arteries: computed tomographic-angiographic findings].
Topics: Aged; Aspirin; Atherectomy, Coronary; Bundle-Branch Block; Coronary Aneurysm; Coronary Angiography; | 2013 |
Ticagrelor in the Real World: The Midland Regional Cardiac Network Experience.
Topics: Adenosine; Aged; Aspirin; Cohort Studies; Dyspnea; Female; Hemorrhage; Humans; Male; Medication Adhe | 2015 |
Acute pulmonary embolism with precordial T-wave inversion and negative D-dimer.
Topics: Aged; Angiography; Anticoagulants; Aspirin; Chest Pain; Diagnosis, Differential; Dyspnea; Electrocar | 2017 |
A 55-Year-Old Woman With Pulmonary Hypertension, Worsening Dyspnea, and Chest Pain.
Topics: Angina Pectoris; Aspirin; Clopidogrel; Compartment Syndromes; Coronary Vessels; Diagnosis, Different | 2014 |
Antiaggregant and anticoagulant therapy of free-floating thrombus in left atrium.
Topics: Adult; Anticoagulants; Aspirin; Clopidogrel; Diagnosis, Differential; Dyspnea; Echocardiography, Tra | 2008 |
Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Therapy, Combination; Dyspnea; Fema | 2008 |
Laryngeal dyspnea in relation to an interaction between acenocoumarol and topical econazole lotion.
Topics: Acenocoumarol; Administration, Topical; Aged, 80 and over; Anticoagulants; Antifungal Agents; Aspiri | 2008 |
Recurrent pericarditis due to natalizumab treatment.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aspirin; Chest Pain; Colchicine; D | 2009 |
A case of food-dependent exercise-induced anaphylaxis due to ingestion of peach.
Topics: Anaphylaxis; Antigens, Plant; Aspirin; Asthma, Exercise-Induced; Child; Cross Reactions; Dyspnea; Ep | 2009 |
Surviving a heart attack: know the signs and save a life.
Topics: Aspirin; Chest Pain; Coronary Angiography; Dizziness; Dyspnea; Echocardiography; Electrocardiography | 2010 |
Calcified ball-like left ventricular thrombus embolized during echocardiography follow-up.
Topics: Aspirin; Atrial Fibrillation; Cardiomegaly; Dyspnea; Echocardiography; Embolization, Therapeutic; He | 2010 |
Paradoxical embolism.
Topics: Aged; Aspirin; Clopidogrel; Dipyridamole; Dyspnea; Echocardiography, Transesophageal; Embolism, Para | 2010 |
Shrinking lung syndrome in pregnancy complicated by antiphospholipid antibody syndrome.
Topics: Adult; Antiphospholipid Syndrome; Aspirin; Cesarean Section; Chest Pain; Dyspnea; Female; Heparin; H | 2011 |
Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Costs and Cost Analysis; Dia | 2011 |
Transient increase in pressure gradients after termination of dual antiplatelet therapy in a patient after transfemoral aortic valve implantation.
Topics: Aged; Aortic Valve Stenosis; Aspirin; Cardiac Catheterization; Clopidogrel; Dyspnea; Echocardiograph | 2012 |
Reversible shortness of breath caused by the antiplatelet agent, clopidogrel.
Topics: Aspirin; Cilostazol; Clopidogrel; Dyspnea; Embolization, Therapeutic; Endovascular Procedures; Human | 2013 |
General adverse reaction to aspirin administered by transdermal iontophoresis.
Topics: Administration, Cutaneous; Adolescent; Analgesics; Angioedema; Aspirin; Cough; Dyspnea; Erythema; Hu | 2002 |
[THE USE OF ASPIRIN IN CHILDREN].
Topics: Aspirin; Child; Dyspnea; Gastroenterology; Hematology; Toxicology; Vomiting | 1964 |
Left ventricular systolic dysfunction and atrial fibrillation in older people in the community--a need for screening?
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Atrial Fibrill | 2004 |
Pulmonary function abnormalities in systemic lupus erythematosus responsive to glucocorticoid therapy.
Topics: Adult; Aspirin; Dyspnea; Glucocorticoids; Humans; Lung; Lupus Erythematosus, Systemic; Male; Pleural | 1981 |
[Clinico-functional data concerning chronic asthmatic bronchitis patients treated wih guacetisal].
Topics: Adult; Aged; Aspirin; Bronchial Spasm; Bronchitis; Cough; Dyspnea; Female; Humans; Male; Middle Aged | 1981 |
Physical activity, dyspnea, and chest pain before and after coronary artery bypass grafting in relation to a history of diabetes.
Topics: Activities of Daily Living; Aspirin; Chest Pain; Coronary Artery Bypass; Diabetic Angiopathies; Dipy | 1998 |
NSAID-induced bronchospasm--a common and serious problem. A report from MEDSAFE, the New Zealand Medicines and Medical Devices Safety Authority.
Topics: Adult; Angioedema; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Bronchial Spasm; Chroni | 1999 |
Life-threatening asthma, urticaria, and angiooedema after ketoprofen.
Topics: Adult; Angioedema; Aspirin; Asthma; Drug Hypersensitivity; Drug Synergism; Dyspnea; Humans; Ketoprof | 1978 |
Lymphocyte aggregation in response to adrenergic stimulation.
Topics: Adenosine Diphosphate; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Arachidonic Acid; Arac | 1988 |
[On the problem of pathogenesis of vagus reflex bradykinin tachypnea].
Topics: Animals; Aspirin; Bradykinin; Bronchial Spasm; Dyspnea; Guinea Pigs; Isoproterenol; Lung; Papaverine | 1966 |
Population studies on drug hypersensitivities.
Topics: Adolescent; Adult; Age Factors; Anaphylaxis; Angioedema; Aspirin; Asthma; Barbiturates; Drug Eruptio | 1973 |
The acute rectal toxicity of acetylsalicylic acid.
Topics: Adrenal Glands; Animals; Aspirin; Ataxia; Body Weight; Brain; Coma; Diarrhea; Diuresis; Dyspnea; Fee | 1966 |